128 related articles for article (PubMed ID: 12613590)
21. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation.
Wang C; Ivanov A; Chen L; Fredericks WJ; Seto E; Rauscher FJ; Chen J
EMBO J; 2005 Sep; 24(18):3279-90. PubMed ID: 16107876
[TBL] [Abstract][Full Text] [Related]
22. MDM2-MDM4 molecular interaction investigated by atomic force spectroscopy and surface plasmon resonance.
Moscetti I; Teveroni E; Moretti F; Bizzarri AR; Cannistraro S
Int J Nanomedicine; 2016; 11():4221-9. PubMed ID: 27621617
[TBL] [Abstract][Full Text] [Related]
23. Real-time surface plasmon resonance monitoring of site-specific phosphorylation of p53 protein and its interaction with MDM2 protein.
Wu L; He Y; Hu Y; Lu H; Cao Z; Yi X; Wang J
Analyst; 2019 Oct; 144(20):6033-6040. PubMed ID: 31502598
[TBL] [Abstract][Full Text] [Related]
24. Targeting the p53-MDM2 interaction to treat cancer.
Klein C; Vassilev LT
Br J Cancer; 2004 Oct; 91(8):1415-9. PubMed ID: 15452548
[TBL] [Abstract][Full Text] [Related]
25. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53.
Li Z; Day CP; Yang JY; Tsai WB; Lozano G; Shih HM; Hung MC
Cancer Res; 2004 Dec; 64(24):9080-5. PubMed ID: 15604276
[TBL] [Abstract][Full Text] [Related]
26. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
[TBL] [Abstract][Full Text] [Related]
27. Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction.
Zhang R; Mayhood T; Lipari P; Wang Y; Durkin J; Syto R; Gesell J; McNemar C; Windsor W
Anal Biochem; 2004 Aug; 331(1):138-46. PubMed ID: 15246006
[TBL] [Abstract][Full Text] [Related]
28. The MDM2-p53 interaction.
Moll UM; Petrenko O
Mol Cancer Res; 2003 Dec; 1(14):1001-8. PubMed ID: 14707283
[TBL] [Abstract][Full Text] [Related]
29. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
[TBL] [Abstract][Full Text] [Related]
30. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53.
Wasylyk C; Salvi R; Argentini M; Dureuil C; Delumeau I; Abecassis J; Debussche L; Wasylyk B
Oncogene; 1999 Mar; 18(11):1921-34. PubMed ID: 10208414
[TBL] [Abstract][Full Text] [Related]
31. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
Vassilev LT; Vu BT; Graves B; Carvajal D; Podlaski F; Filipovic Z; Kong N; Kammlott U; Lukacs C; Klein C; Fotouhi N; Liu EA
Science; 2004 Feb; 303(5659):844-8. PubMed ID: 14704432
[TBL] [Abstract][Full Text] [Related]
32. Small molecule inhibitors of p53/MDM2 interaction.
Fotouhi N; Graves B
Curr Top Med Chem; 2005; 5(2):159-65. PubMed ID: 15853644
[TBL] [Abstract][Full Text] [Related]
33. Comparative study of the p53-mdm2 and p53-MDMX interfaces.
Böttger V; Böttger A; Garcia-Echeverria C; Ramos YF; van der Eb AJ; Jochemsen AG; Lane DP
Oncogene; 1999 Jan; 18(1):189-99. PubMed ID: 9926934
[TBL] [Abstract][Full Text] [Related]
34. MDM2 interacts with MDMX through their RING finger domains.
Tanimura S; Ohtsuka S; Mitsui K; Shirouzu K; Yoshimura A; Ohtsubo M
FEBS Lett; 1999 Mar; 447(1):5-9. PubMed ID: 10218570
[TBL] [Abstract][Full Text] [Related]
35. Stapled peptides with improved potency and specificity that activate p53.
Brown CJ; Quah ST; Jong J; Goh AM; Chiam PC; Khoo KH; Choong ML; Lee MA; Yurlova L; Zolghadr K; Joseph TL; Verma CS; Lane DP
ACS Chem Biol; 2013 Mar; 8(3):506-12. PubMed ID: 23214419
[TBL] [Abstract][Full Text] [Related]
36. Peptide activators of the p53 tumor suppressor.
Zhan C; Lu W
Curr Pharm Des; 2011; 17(6):603-9. PubMed ID: 21391910
[TBL] [Abstract][Full Text] [Related]
37. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.
Liu Z; Olejniczak ET; Fesik SW
Protein Expr Purif; 2004 Oct; 37(2):493-8. PubMed ID: 15358376
[TBL] [Abstract][Full Text] [Related]
38. Sequence-specific 1H, 15N, and 13C assignment of the N-terminal domain of the human oncoprotein MDM2 that binds to p53.
Stoll R; Renner C; Mühlhahn P; Hansen S; Schumacher R; Hesse F; Kaluza B; Engh RA; Voelter W; Holak TA
J Biomol NMR; 2000 May; 17(1):91-2. PubMed ID: 10909873
[No Abstract] [Full Text] [Related]
39. Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2.
Clark PA; Llanos S; Peters G
Oncogene; 2002 Jul; 21(29):4498-507. PubMed ID: 12085228
[TBL] [Abstract][Full Text] [Related]
40. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.
Zhang Y; Xiong Y; Yarbrough WG
Cell; 1998 Mar; 92(6):725-34. PubMed ID: 9529249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
